Neuropathic Pain Assessment and Management

Neuropathic pain arises as a direct consequence of a lesion or disease affecting the somatosensory system and presents with diverse symptoms including burning sensations, electric shocks and heightened sensitivity. Accurate assessment combines detailed clinical history, validated screening questionnaires, comprehensive sensory examination and, increasingly, digital tools for mapping pain distribution. Confirmatory tests such as nerve conduction studies and advanced imaging elucidate structural and functional nerve alterations, while emerging biochemical markers aim to quantify axonal injury objectively. Management adopts a multimodal strategy tailored to aetiology and patient profile. First-line pharmacotherapy includes gabapentinoids, tricyclic antidepressants and selective serotonin–noradrenaline reuptake inhibitors, which modulate aberrant neural signalling. Interventional approaches such as peripheral nerve blocks, spinal cord stimulation and neuromodulation address refractory cases. Rehabilitation and psychological support reinforce coping strategies within a biopsychosocial framework. Ongoing integration of patient-reported outcomes and remote monitoring enhances individualised care pathways and long-term quality of life.

Research from Nature Portfolio

Recent investigations have evaluated neuroaxonal biomarkers in diabetic polyneuropathy. One study measured serum neurofilament light chain to determine its association with pain severity. Although levels did not correspond to current pain intensity, elevated concentrations correlated with poor glycaemic control and renal impairment, indicating that this marker reflects systemic nerve injury rather than subjective pain. These findings emphasise the need to identify alternative objective biomarkers for neuropathic pain assessment and to refine therapeutic targeting based on underlying neurodegeneration.

Neuropathic Pain Assessment and Management publication trend

The graph below shows the total number of articles in neuropathic pain assessment and management across all publications each year (not limited to Nature Index journals).

Technical terms

Neuropathic pain: Pain caused by a lesion or disease of the somatosensory nervous system.

Serum neurofilament light chain (NfL): A cytoskeletal protein released into blood following axonal injury, used as a biomarker of neurodegeneration.

Digital pain drawing: An electronic tool enabling patients to shade areas of pain on a body chart for quantitative analysis.

painDETECT: A patient-reported questionnaire designed to screen for neuropathic pain components.

DN4 (Douleur Neuropathique 4): A clinician-administered screening tool combining interview items and sensory tests to identify neuropathic pain.

References

1. A novel mobile phone and tablet application for automatized calculation of pain extent. Computers in Biology and Medicine (2023).
2. The limited role of serum neurofilament light chain in predicting pain severity of patients with diabetic polyneuropathy. Scientific Reports (2024).
3. Factors correlated with neuropathic pain among industrial workers in Vietnam: a multi-site cross-sectional study. Frontiers in Public Health (2023).
4. Neuropathic pain. Pain (2016).